Evaluation of anti-inflammatory effect of flavonoid content of Mango leaf extract (Mangifera indica) on inflammation of airways in patients with coronavirus under home care

Determining the effect of flavonoid content of Mangifera indica leaf extract by prescribing capsules containing 100 mg of extract on the course of the disease, symptomatic treatment and reduction of inflammatory mediators in COVID-19 patients under home care

The double-blind clinical trial, two treatment groups and parallel control, The stage will be over 60 patients. For randomization, we will use the method of permutation blocks with a number of 6 blocks using Random allocation software.

Patients with COVID19 under home care are divided into groups A and B. The anti-inflammatory effects of mango leaf extract will be evaluated with 100 mg capsules. The study will be blinded at the level of outcome assessor and statistical analyst of results. Location: Fasa University of Medical Sciences

Admission requirements: Definitive diagnosis of COVID-19 2. Age over 18 years 3. Both sexes (male and female) 4. Having informed and written consent to participate in the study 5. No history of any allergies 6. Do not take anticoagulants 7. Not getting pregnant and breastfeeding 8. No diabetes in the person Conditions for not entering the study: 1. Disagreement of the physician in charge of the patient 2. History of any allergies 3. History of heart and kidney disease 4. Patient dissatisfaction 5. History of high blood pressure

Divide patients into two similar groups A and B. The treatment group contains capsules containing 100 mg of plant leaf extract (Mangifera indica) and the placebo group contains 100 mg capsules containing fried corn flour. By introducing the plan and justifying the patient, written consent is received.

1. hospitalization in medical centers with natural activity 2. Degree of hemoglobin saturation (SPO2) in the normal range

This study is performed on patients referred to health centers and infectious disease specialists in the present study. For patients under home care, the hospital code along with the relevant information (medication regimen, age and sex, severity of the disease and severity of symptoms) is provided by the expert to the patient. The relevant expert divides the patients into two similar groups based on the treatment regimen, age group, sex, severity of the disease and symptoms, and randomly divides one group into group A and one group into group B using the patient code numbers. For randomization, the permutation block method with the number of blocks of 6 is done using Random allocation software.

For blinding, the study of the drug (capsules containing 100 mg of Mangifera indica leaf extract ) and placebo (including roasted corn flour capsules) with the names A and B in the same package are prescribed by the doctor to the patient.) Capsules according to The principles of pharmacy are created by a pharmacist.) A patient-level study, outcome evaluator, and statistical analyst of the results will be blind. Only the manufacturer of the drug can decode the contents of each capsule based on the original retained form of the randomization results The person in charge of drug delivery and the patient, the doctor, the person in charge of evaluating the consequences will not be aware of the coding. The results of the two groups under the headings of groups A and B will be delivered to the statistical analyzer.

Some of the information obtained will be available based on changes in initial outcomes.

Start of access period 6 months after production and publication of results

People engaged in research in medical universities of the country

The methods and data contained in this clinical trial should be used solely to advance similar projects. It is also necessary to mention the research center of this study (Fasa University of Medical Sciences) if information is used

Dr. Seyyed Amin Kouhpayeh Email address: kouhpayeha@gmail.com Contact number: 09177087247 Address: Department of Pharmacology, Fasa University of Medical Sciences and Health Services, Fasa, Iran. Email Address: Amindakhiliardestani@yahoo.com Contact number: 09228584505 Address: Fasa University, Fasa University of Medical Sciences and Health Services, Fasa, Iran.

1. Contact the scientific or general respondent of the study 2. Sending their official request to the respondent 3. Apply to the University Research Council 4. In case of a positive response from the council, it will be provided to the applicant in accordance with the ethical principles. 5. The total duration of the process from the time of receiving the request is 20 days.